Company news
Shield Therapeutics PLC news in 2026
Shield Therapeutics PLC's news releases, calls and decks from 2026, newest first.
Q3 2026 Trading Update
November 3, 2026
Total Voting Rights
October 30, 2026
Total Voting Rights
September 30, 2026
Shield assumes full control of ACCRUFeR® in the US
August 27, 2026
Interim results for the six months ended 30 Jun 26
August 20, 2026
Q2 and H1 2026 Trading Update
July 30, 2026
ACCRUFeR® Phase 3 pediatric trial published
July 28, 2026
Results of 2026 Annual General Meeting
June 18, 2026
Q1 2026 Trading Update
May 1, 2026
Enrollment in Phase II Clinical Trial for ACCRUFeR
April 27, 2026
Audited results for year ended 31 December 2025
April 9, 2026
Publication of Report, Reinforcing FDA Approval
April 1, 2026
Total Voting Rights
March 31, 2026
Chinese NMPA Accepts MAA Submission for ACCRUFeR®
March 3, 2026
FDA Grants additional Exclusivity for ACCRUFeR
February 9, 2026
Approval for ACCRUFeR in China expected in Q1 2026
January 30, 2026
Q4 2025 Trading Update
January 21, 2026
Block listing 6 Monthly Return
January 2, 2026